# Clinical trial search, site verification and screening

Source: https://onco.cc/terms/trial-search-site-verification/  
OnCo record `trial-search-site-verification` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A trial search identifies studies to examine. The study team must separately check the relevant site, cohort and full eligibility requirements.

## Summary

NCI describes finding a study, discussing it with the team, informed consent and formal screening as distinct steps. A registry identifier helps distinguish studies, while the dated protocol and record describe the design and entry rules. Overall recruiting status can reflect an open facility elsewhere; it does not establish an available place in the relevant local cohort. A matching diagnosis or biomarker is only part of eligibility. Medical-history review and required tests can still exclude participation after an initial discussion.

## Fields

- Kind: Term
- Last checked: 2026-11-11
- Also known as: finding a clinical trial; trial-site verification; trial prescreening; trial screening and enrollment

## Notes

- Search with disease, treatment setting, intervention aliases, biomarker and location terms. Keep registry verification and update dates with the result; ask the team about the current protocol, site and cohort. A record or invitation to screen is not a promise of enrollment.
- Estimated enrollment is a target total, while actual enrollment records people already enrolled. Neither is a count of places available now. Overall study recruitment, an individual facility’s status and availability in the relevant cohort or dose group require separate dated checks.
- When a protocol randomizes participants, meeting its entry rules does not reserve the experimental arm. Assignment follows the protocol’s chance process rather than a choice by the participant or doctor. Screening, eligibility, enrollment, arm assignment and individual benefit are different steps; a plausible match or invitation to screen does not establish the later steps.
- Keep a compact screening record: registry number and title, current protocol version, disease and stage, treatment goal and required biomarker. Ask about previous treatments, relevant conditions and safety history, current medicines, laboratory criteria and required samples. Advanced-disease and postoperative studies can share a biomarker while requiring different measurable disease, pathology or enrolment windows. A washout is the interval defined by that protocol after a named treatment or medicine; its starting event and duration must be checked with the treating and study teams. A deadline or a half-life calculation is not permission to change treatment.
- Confirm the relevant site, cohort and slot, each assignment group and the randomisation ratio, screening and visit dates, treatment duration and follow-up. Check travel, sample needs, available support and who pays. Record who supplied each dated answer and what remains unknown; request the current protocol or consent material and clarify discrepancies between it, the registry and the site. A personal eligibility worksheet prepares that discussion and does not replace formal screening.
- In a fictional postoperative study, a matching molecular report is a reason to ask about screening, not proof of pathology, treatment-history, local availability or timing eligibility. If Drug B plus standard care is randomised against standard care alone, either group can be assigned; neither the doctor nor participant chooses the experimental arm. If a multicohort registry says recruiting but the local breast cohort has no slots, access is unconfirmed. Asking about another site or reopening supplies a next question, not a promise. Trial phase describes the research question rather than an individual benefit estimate.

## Sources

- NCI: steps to find a clinical trial: https://www.cancer.gov/research/participate/clinical-trials-search/steps
- NCI: what to expect during a clinical trial: https://www.cancer.gov/research/participate/clinical-trials/what-to-expect
- ClinicalTrials.gov: protocol registration definitions: https://clinicaltrials.gov/policy/protocol-definitions
- 42 CFR 11.10: overall recruitment and individual-site status: https://www.govinfo.gov/content/pkg/CFR-2025-title42-vol1/pdf/CFR-2025-title42-vol1-sec11-10.pdf
- NCI: eligibility, randomization and clinical-trial comparisons: https://www.cancer.gov/research/participate/clinical-trials/how-trials-work
- NCI: research, routine-care and practical costs of a trial: https://www.cancer.gov/research/participate/clinical-trials/paying

## Connected records

- terms: [Accrual and enrolment](https://onco.cc/terms/accrual/), [Clinical trial](https://onco.cc/terms/clinical-trial/), [Expanded access (compassionate use)](https://onco.cc/terms/expanded-access/), [Investigational New Drug application](https://onco.cc/terms/investigational-new-drug-application/), [Right to Try Act 2018 and state right-to-try laws](https://onco.cc/terms/right-to-try/), [Trial protocol and statistical analysis plan](https://onco.cc/terms/trial-protocol/), [Trial registration and results reporting (ClinicalTrials.gov, EU CTR)](https://onco.cc/terms/trial-registration/)

---
JSON: https://onco.cc/api/v1/entities/trial-search-site-verification.json